UPDATE: BofA/Merrill Lynch Downgrades Cliffs Natural Resources (CLF) to Underperform
Tweet
Share
E-mailGet Alerts CLF Hot Sheet
Price: $11.17 --0%
Rating Summary:
5 Buy, 16 Hold, 9 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 11 | New: 19
Rating Summary:
5 Buy, 16 Hold, 9 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 11 | New: 19
Join SI Premium – FREE
(Updated - June 19, 2013 8:04 AM EDT)
BofA/Merrill Lynch downgraded Cliffs Natural Resources (NYSE: CLF) from Neutral to Underperform with a price target of $16 (from $24). Analyst Timna Tanner noted the high cost of iron ore and met production at Cliffs, and he thinks the company will struggle to compete with new Australia capacity. Despite the downgrade, he sees no reason for a "liquidity panic."
For an analyst ratings summary and ratings history on Cliffs Natural Resources click here. For more ratings news on Cliffs Natural Resources click here.
Shares of Cliffs Natural Resources closed at $18.59 yesterday.
BofA/Merrill Lynch downgraded Cliffs Natural Resources (NYSE: CLF) from Neutral to Underperform with a price target of $16 (from $24). Analyst Timna Tanner noted the high cost of iron ore and met production at Cliffs, and he thinks the company will struggle to compete with new Australia capacity. Despite the downgrade, he sees no reason for a "liquidity panic."
For an analyst ratings summary and ratings history on Cliffs Natural Resources click here. For more ratings news on Cliffs Natural Resources click here.
Shares of Cliffs Natural Resources closed at $18.59 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Upgrades Etsy (ETSY) to Buy, 'Still Room to Run'
- BofA Securities Downgrades Gerdau S.A. (GGBR4:BZ) (GGB) to Neutral
- Jefferies Starts Anthem Biosciences (ANTHEM:IN) at Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT Change, Downgrades, Hot DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
